Choose an Affordable Anti-Herpes Product; polyDNA Recommends Gene-Eden-VIR - Insurance News | InsuranceNewsNet

InsuranceNewsNet — Your Industry. One Source.™

Sign in
  • Subscribe
  • About
  • Advertise
  • Contact
Home Now reading Newswires
Topics
    • Advisor News
    • Annuity Index
    • Annuity News
    • Companies
    • Earnings
    • Fiduciary
    • From the Field: Expert Insights
    • Health/Employee Benefits
    • Insurance & Financial Fraud
    • INN Magazine
    • Insiders Only
    • Life Insurance News
    • Newswires
    • Property and Casualty
    • Regulation News
    • Sponsored Articles
    • Washington Wire
    • Videos
    • ———
    • About
    • Meet our Editorial Staff
    • Advertise
    • Contact
    • Newsletters
  • Exclusives
  • NewsWires
  • Magazine
  • Newsletters
Sign in or register to be an INNsider.
  • AdvisorNews
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Exclusives
  • INN Magazine
  • Insurtech
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Video
  • Washington Wire
  • Life Insurance
  • Annuities
  • Advisor
  • Health/Benefits
  • Property & Casualty
  • Insurtech
  • About
  • Advertise
  • Contact
  • Editorial Staff

Get Social

  • Facebook
  • X
  • LinkedIn
Newswires
Newswires RSS Get our newsletter
Order Prints
December 30, 2013 Newswires
Share
Share
Post
Email

Choose an Affordable Anti-Herpes Product; polyDNA Recommends Gene-Eden-VIR

PR Web

Rochester, NY (PRWEB) December 30, 2013

polyDNA recommends Gene-Eden-VIR as the most affordable means of treating a latent herpes infection. As the winter holidays pass, and people break the bank on presents, polyDNA is doing its part to make it easy for individuals to afford a natural remedy against the latent herpes virus.

This week, the media, government agencies, not-for-profits, schools, financial institutions and businesses of all kinds are putting up “After Christmas Sales” or are reminding people why their products or services are better than someone else’s. To help customers who suffer from herpes infections, polyDNA compared the cost of Valtrex, Acyclovir (Zovirax), and Gene-Eden-VIR. The first two are FDA approved medications while the third is a natural, antiviral remedy. The first two target the active herpes virus, while the third was designed to target the latent virus.

“I spent so much money on my kids this Christmas! Somehow, the threat of a herpes outbreak kind of got pushed to the back of my mind. I know for sure I won’t have the money to afford Valtrex over the next few months, and that’s especially true since I lost my insurance too. Things just seem to get harder and harder!” – Tamicka R.

According to goodrx.com, the cost of a month’s supply of Valtrex (90 pills), one of the most common anti-herpes medications, is $1401.00 for the brand name at the CVS Pharmacy. (1) The cost of the generic brand is only slightly less.

While Zovirax (Acyclovir) is significantly cheaper, this herpes medication still costs at least $148.41 for oral suspension. (2)

Gene-Eden-VIR is the only natural antiviral product that was tested according to FDA guidelines for safety and efficacy. A month’s supply of Gene-Eden-VIR is $37.99. That’s $110.42 cheaper than Zovirax, and well over $1,000 cheaper than Valtrex.

“We recommend that individuals make New Year’s resolutions that improve their bank account. Choosing Gene-Eden-VIR, an affordable, clinically proven herpes remedy, is a great way to live up to that sort of resolution.” – Mike Evans, polyDNA

In a post marketing clinical study published on August 12, 2013 in the peer reviewed medical journal Pharmacology & Pharmacy in a special edition on Advances in Antiviral Drugs, researchers showed that Gene-Eden-VIR is safe and effective (3). Additionally, up to 70% of those studied reported a decrease in viral symptoms, and users experienced an increase in overall health (3).

Each ingredient of Gene-Eden-VIR was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent form of herpes. (3)

To learn more about Gene-Eden-VIR, visit http://www.gene-eden-kill-virus.com. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

Reference:

(1)    Goodrx.com - Prices for 90 tablets of Valtrex 1g (brand).
         http://www.goodrx.com/valacyclovir#/?filter-location=&coords=&label=Valtrex&form=tablet&strength=1g&quantity=custom&qty-custom=90

(2)    Goodrx.com - Prices for 200 ml of 200mg/5ml Zovirax oral suspension (brand).
         http://www.goodrx.com/acyclovir#/?filter-location=&coords=&label=Zovirax&form=oral+suspension&strength=200mg&quantity=custom&qty-custom=30

(3) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing
Clinical Study. Published on August 12, 2013.
     http://gene-eden-kill-virus.com/PP_Gene-Eden-VIR-is-Antiviral.pdf

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

Read the full story at http://www.prweb.com/releases/2013/12/prweb11449868.htm

Copyright:  (c) 2013 PRWEB.COM Newswire
Wordcount:  598

Advisor News

  • Proposed legislation takes aim at Social Security shortfall
  • The overlooked retirement security risk that must be addressed
  • What advisors should know about hedge funds in retirement planning
  • Retirement control is top success measure for middle class, ACLI says
  • Industry groups applaud House passage of Financial Exploitation Prevention Act
More Advisor News

Annuity News

  • Built-in guaranteed annuities: What advisors should know
  • Malibu Life Holdings Completes Acquisition of TruSpire, Establishing Malibu USA and Accelerating Entry into the U.S. Retail Annuity Market
  • Why job boards are failing insurance agencies
  • MassMutual Ranks No. 100 on the 2026 Fortune 500® List
  • What’s fueling record annuity growth?
More Annuity News

Health/Employee Benefits News

  • Coalition sues to protect Medicaid coverage
  • Findings from George Washington University Update Understanding of Managed Care (Eligibility Assistance Increases Insurance Enrollment Within Community Health Centers but Not At the State Level): Managed Care
  • Findings from Razanne Oueini and Colleagues Provides New Insights into Proinsulin (Changes in persistence to basal insulin following the Medicare out-of-pocket cost cap): Peptide Proteins – Proinsulin
  • Researchers from Columbia University Detail New Studies and Findings in the Area of Managed Care (The Impact of Health Shocks On Housing Instability: Evidence From Urban Medicaid Enrollees): Managed Care
  • Studies Conducted at Stanford University on Economics Recently Reported (Why Doesn’t the United States Have National Health Insurance? the Political Role of the American Medical Association): Economics
More Health/Employee Benefits News

Life Insurance News

  • Fortitude Re Announces $3.8 Billion Long-Term Care Reinsurance Agreement with Unum Group
  • Unum Group Announces $3.8 Billion Long-Term Care Reinsurance Transaction with Fortitude Re
  • Before you debate premium financing, understand the bigger picture
  • NAIFA praises House committee approval of Clarity for Compensation Act
  • PHL Variable liquidation pushed out to 2027, Connecticut regulators say
More Life Insurance News

NEWS INSIDE

  • Companies
  • Earnings
  • Economic News
  • INN Magazine
  • Insurtech News
  • Newswires Feed
  • Regulation News
  • Washington Wire
  • Videos

FEATURED OFFERS

Life moves fast. Your BGA should, too.
Stay ahead with Modern Life's AI-powered tech and expert support.

A MYGA for Clients Hesitant to Commit to One Long-Term Rate
First-year certainty. Annual rate updates. Get the CurrentRate® MYGA Sales Kit.

Elite Networking & Insights Await at the Event of the Year
The industry's premier conference for leaders driving what’s next in financial services.

Press Releases

  • Prosperity Life GroupSM Launches Prosperity PathWaySM Series, Bringing Greater Choice and Flexibility to Retirement Income Planning
  • Senior Market Sales® Fortifies Annuity Reach With Acquisition of Retirement Planning Firm Stratton & Company
  • RFP #T01625
  • Rockwood Programs Appoints Kerry Ladouceur as Vice President, Financial Lines
  • JP Insurance Group Launches Commercial Property & Casualty Division; Appoints Joe Webster as Managing Director
More Press Releases > Add Your Press Release >

How to Write For InsuranceNewsNet

Find out how you can submit content for publishing on our website.
View Guidelines

Topics

  • Advisor News
  • Annuity Index
  • Annuity News
  • Companies
  • Earnings
  • Fiduciary
  • From the Field: Expert Insights
  • Health/Employee Benefits
  • Insurance & Financial Fraud
  • INN Magazine
  • Insiders Only
  • Life Insurance News
  • Newswires
  • Property and Casualty
  • Regulation News
  • Sponsored Articles
  • Washington Wire
  • Videos
  • ———
  • About
  • Meet our Editorial Staff
  • Advertise
  • Contact
  • Newsletters

Top Sections

  • AdvisorNews
  • Annuity News
  • Health/Employee Benefits News
  • InsuranceNewsNet Magazine
  • Life Insurance News
  • Property and Casualty News
  • Washington Wire

Our Company

  • About
  • Advertise
  • Contact
  • Meet our Editorial Staff
  • Magazine Subscription
  • Write for INN

Sign up for our FREE e-Newsletter!

Get breaking news, exclusive stories, and money- making insights straight into your inbox.

select Newsletter Options
Facebook Linkedin Twitter
© 2026 InsuranceNewsNet.com, Inc. All rights reserved.
  • Terms & Conditions
  • Privacy Policy
  • InsuranceNewsNet Magazine

Sign in with your Insider Pro Account

Not registered? Become an Insider Pro.
Insurance News | InsuranceNewsNet